Indeed, pre-clinical and clinical findings show that oncolytic vectors can trigger anti-tumor immunity and increase immune cell infiltration (including cytotoxic CD8+ T cells) into the tumor microenvironment (TME). This evidence concerns the gene CD8A and neoplasm.